VRX Share Price

Open 18.15 Change Price %
High 20.84 1 Day 2.29 12.57
Low 18.09 1 Week 3.71 22.08
Close 20.51 1 Month 2.55 14.20
Volume 3767090 1 Year -7.83 -27.63
52 Week High 42.25
52 Week Low 11.20
VRX Important Levels
Resistance 2 23.06
Resistance 1 22.01
Pivot 19.81
Support 1 19.01
Support 2 17.96
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
BBD-B 2.39 -3.63%
HCG 19.00 27.18%
HCG 19.00 27.18%
HCG 19.00 27.18%
HCG 19.00 27.18%
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
HE 0.04 100.00%
HE 0.04 100.00%
TVI 0.02 100.00%
LRT-UN 0.04 100.00%
HCG 19.00 27.18%
HCG 19.00 27.18%
HCG 19.00 27.18%
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
DNT 0.06 -14.29%
BLU 0.36 -12.20%
GGA 0.08 -11.11%
CTU-A 0.19 -9.52%
DEJ 0.14 -6.67%
DEJ 0.14 -6.67%
BU 1.45 -6.45%
GEN 0.15 -6.25%
GEN 0.15 -6.25%

Valeant Pharmaceuticals (TSE: VRX)

VRX Technical Analysis 2
As on 22nd Jun 2017 VRX Share Price closed @ 20.51 and we RECOMMEND Sell for LONG-TERM with Stoploss of 22.85 & Strong Buy for SHORT-TERM with Stoploss of 15.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRX Target for June
1st Target up-side 20.29
2nd Target up-side 23.02
3rd Target up-side 25.75
1st Target down-side 12.51
2nd Target down-side 9.78
3rd Target down-side 7.05
VRX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.valeant.com
VRX Address
2150 St. Elz
Laval, QC H7L 4A8
Phone: 514-744-6792
Fax: 514-744-6272
VRX Latest News
Does Valeant Pharmaceuticals Intl Inc (VRX) Stock Have a Bull Case?   Investorplace.com   - 22nd Jun 17
Valeant Pharmaceuticals Intl Inc's (VRX) Bausch + Lomb Named Most Trusted ...   Smarter Analyst   - 22nd Jun 17
BlackBerry Ltd, Netflix, Inc. And Valeant Pharmaceuticals Intl Inc - Today's ...   Amigobulls   - 22nd Jun 17
Valeant: Let's Talk Pipeline And Value   Seeking Alpha   - 21st Jun 17
Valeant: Is This Time Different?   Seeking Alpha   - 20th Jun 17
Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor ...   PR Newswire (press release)   - 20th Jun 17
Valeant: Was Inova Sale The Worst Deal Ever?   Seeking Alpha   - 16th Jun 17
Valeant: Just Short It   Seeking Alpha   - 14th Jun 17
Valeant: The Market Wants Growth   Seeking Alpha   - 14th Jun 17
Why Valeant Pharmaceuticals Intl. Inc. Jumped Higher Today   Motley Fool   - 09th Jun 17
Interactive Technical Analysis Chart Valeant Pharmaceuticals ( VRX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Valeant Pharmaceuticals
VRX Business Profile
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.